Office for Research and Innovation
Office for Research and Innovation
About the Office for Research and Innovation
Grants Management
Grants Management
Grants Submission
Regulatory Affairs Unit
About Regulatory Affairs
IRB
IACUC
IBC
Health & Safety
Services & Support Unit
Services & Support Unit
Tech Transfer
Tech Transfer
JHCPU
JHCPU
Research and Innovation Centers
Clinical & Translational Research
Community & Public Health
Healthcare Education
Research Themes
Basic Sciences
Clinical & Translational Sciences
Public Health & Social Sciences
Sponsored Institutional Research Programs
Federal
Core Facilities and Resources
Meharry Shared Resources
Collaborative Institutional Resources
- About Collaborative Institutional Resources
Summer Research

Meharry Cancer Summer Research Program (SuRP)

Enhancing Virology Training Summer Research Program (ENVIT)
New Initiatives

AIM-AHEAD

Accelerate Precision Health (CZ1)

DHGI Together for CHANGE

Beacon of Hope

NSF Innovation-Corps

Dry January USA
The Research Digest
Get Involved
Contact Us
Donate

NLM Publications / The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.

The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.